Free shipping on all orders over $ 500

MKC-1

Cat. No. M28046
MKC-1 Structure
Synonym:

Ro-31-7453

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family.

Chemical Information
Molecular Weight 400.39
Formula C22H16N4O4
CAS Number 125313-92-0
Form Solid
Solubility (25°C) DMSO ≥ 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Flora Zagouri, et al. Gynecol Oncol. mTOR inhibitors in breast cancer: a systematic review

[2] Jason E Faris, et al. Invest New Drugs. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

[3] Amye Tevaarwerk, et al. Invest New Drugs. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

[4] Min Wang, et al. Nucl Med Biol. The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent

[5] A Tomillero, et al. Methods Find Exp Clin Pharmacol. Gateways to clinical trials

Related Akt Products
LY2780301

LY2780301 is an oral dual-target inhibitor of AKT/RSK that binds to and inhibits the activity of Akt, thereby inhibiting the PI3K/Akt signaling pathway, which in turn inhibits cell proliferation and induces apoptosis in tumor cells, and possesses antitumor activity.

Akt/SKG Substrate Peptide

Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Adropin (34-76) (human, mouse, rat)

Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle.

Apoptin-derived peptide

Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity.

TAT-TCL1-Akt-in

TAT-TCL1-Akt-in is an Akt inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: MKC-1, Ro-31-7453 supplier, Akt, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.